Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR
Daniele Generali(University of Trieste), Albane Frati(Sorbonne Université), Giovanni Allevi(Istituti Ospitalieri di Cremona), Sergio Aguggini(Istituti Ospitalieri di Cremona), Roman Rouzier(Institut Curie), Carla Strina(Istituti Ospitalieri di Cremona), Silvia Paola Corona(Hôpital Cardiologique du Haut-Lévêque), Manuela Milani(Humanitas University), Lajos Pusztai(Yale University)
Cited by 5
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
|Journal of Clinical Oncology|2007|1.6k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830